WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia ® (finerenone) as a potential treatment for heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results